Daewoong Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Daewoong Pharmaceutical wird ein jährliches Gewinn- und Umsatzwachstum von 14.6% bzw. 4.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.3% betragen.

Wichtige Informationen

14.6%

Wachstumsrate der Gewinne

14.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	33.3%
Wachstumsrate der Einnahmen	4.7%
Zukünftige Eigenkapitalrendite	12.3%
Analystenabdeckung	Good
Zuletzt aktualisiert	01 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)

Nov 22

There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price

Nov 06

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Oct 15

Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 13

Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings

Jul 24

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Jul 04

Gewinn- und Umsatzwachstumsprognosen

KOSE:A069620 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (KRW Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,521,022	126,868	129,886	177,583	5
12/31/2025	1,402,804	112,227	120,367	161,883	5
12/31/2024	1,300,481	74,554	78,156	129,200	5
9/30/2024	1,416,626	103,573	-178,610	42,453	N/A
6/30/2024	1,399,052	90,872	-130,838	84,726	N/A
3/31/2024	1,388,699	114,474	-53,452	126,812	N/A
12/31/2023	1,375,329	121,739	-19,618	136,009	N/A
9/30/2023	1,341,290	46,381	43,333	170,054	N/A
6/30/2023	1,332,284	51,305	19,019	136,131	N/A
3/31/2023	1,304,151	44,030	6,342	118,959	N/A
12/31/2022	1,280,092	42,240	6,162	118,215	N/A
9/30/2022	1,255,325	82,107	-13,414	87,701	N/A
6/30/2022	1,214,081	72,576	-65	78,402	N/A
3/31/2022	1,181,714	61,231	-25,785	65,359	N/A
12/31/2021	1,152,976	24,506	-34,727	39,994	N/A
9/30/2021	1,117,201	11,539	-21,549	45,667	N/A
6/30/2021	1,103,387	2,971	-8,568	68,925	N/A
3/31/2021	1,067,635	-11,030	20,341	81,301	N/A
12/31/2020	1,055,424	12,753	43,714	100,981	N/A
9/30/2020	1,075,831	-1,657	-2,683	53,237	N/A
6/30/2020	1,068,433	-2,480	2,987	49,749	N/A
3/31/2020	1,107,158	16,828	13,031	57,437	N/A
12/31/2019	1,113,426	22,006	8,989	57,600	N/A
9/30/2019	1,098,180	-8,021	81,272	126,212	N/A
6/30/2019	1,086,724	-6,314	33,847	97,101	N/A
3/31/2019	1,055,675	-12,079	2,178	66,602	N/A
12/31/2018	1,031,427	-15,152	-8,863	47,500	N/A
9/30/2018	995,896	19,610	-8,088	49,029	N/A
6/30/2018	990,152	25,296	N/A	48,832	N/A
3/31/2018	973,800	31,077	N/A	82,155	N/A
12/31/2017	960,307	31,581	N/A	103,938	N/A
9/30/2017	959,672	39,318	N/A	60,986	N/A
6/30/2017	927,950	34,453	N/A	49,717	N/A
3/31/2017	898,632	27,433	N/A	21,664	N/A
12/31/2016	883,920	26,970	N/A	15,377	N/A
9/30/2016	862,689	19,704	N/A	19,176	N/A
6/30/2016	869,026	26,021	N/A	43,180	N/A
3/31/2016	857,252	34,413	N/A	44,974	N/A
12/31/2015	839,686	42,930	N/A	35,888	N/A
9/30/2015	812,337	44,657	N/A	21,960	N/A
6/30/2015	778,975	28,576	N/A	26,489	N/A
3/31/2015	758,475	30,555	N/A	36,310	N/A
12/31/2014	735,889	31,544	N/A	25,945	N/A
9/30/2014	734,716	31,176	N/A	42,933	N/A
6/30/2014	714,185	56,700	N/A	21,313	N/A
3/31/2014	690,275	58,808	N/A	24,093	N/A
12/31/2013	682,508	58,400	N/A	54,157	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: A069620Das prognostizierte Gewinnwachstum (14.6% pro Jahr) liegt über der Sparquote (2.7%).

Ertrag vs. Markt: A069620Die Erträge des Unternehmens (14.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt KR (28.4% pro Jahr).

Hohe Wachstumserträge: A069620Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: A069620Die Einnahmen des Unternehmens (4.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt KR (9.4% pro Jahr).

Hohe Wachstumseinnahmen: A069620Die Einnahmen des Unternehmens (4.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: A069620Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.3%).

Daewoong Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.8% to ₩190,000

Price target increased by 11% to ₩176,250

Consensus EPS estimates increase by 25%

Price target decreased by 7.5% to ₩171,083

Price target decreased by 7.4% to ₩205,714

Consensus forecasts updated

Recent updates

Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)

There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price

Price target increased by 7.8% to ₩190,000

Price target increased by 11% to ₩176,250

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 19%

Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate

Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-In-Class PRS Inhibitor, Bersiporocin

Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings

Investor sentiment improves as stock rises 19%

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Consensus EPS estimates increase by 25%

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Upcoming dividend of ₩600 per share at 0.5% yield

Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-Dose Administration of Nabota

Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy

Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

Price target decreased by 7.5% to ₩171,083

Daewoong Pharmaceutical Obtains Approval for SGLT2i + Metformin Combination Drug Envlomet

New minor risk - Shareholder dilution

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023

Full year 2022 earnings released: EPS: ₩3,816 (vs ₩2,227 in FY 2021)

Now 20% undervalued after recent price drop

Price target decreased by 7.4% to ₩205,714

Investor sentiment deteriorates as stock falls 18%

Daewoong Pharmaceutical Begins the First Administration of Bersiporocin

Daewoong Pharmaceutical Co.,Ltd Submits NDA for Its Global New Drug Fexuclue in 11 Countries, Only 1 Year After Approval in Korea

Consensus forecasts updated

Upcoming dividend of ₩600 per share

Daewoong Pharmaceutical Announces Success in Developing New Antidiabetic Medication

Now 20% undervalued after recent price drop

Less than half of directors are independent

Daewoong Pharmaceutical Announces Phase 3 Clinical Trial Results of New Diabetes Treatment Enavogliflozin

Investor sentiment improved over the past week

Price target increased to ₩235,714

Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-In-Class Irreversible Oral Dual Acting Inhibitor for Autoimmune Diseases

Price target increased to ₩235,000

Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug

Investor sentiment improved over the past week

Less than half of directors are independent

Daewoong Pharmaceutical Submits NDA for its Global New Drug Fexuclue Tablets to the Philippines

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Daewoong pharmaceutical Co.,Ltd Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy

Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug

Upcoming dividend of ₩600 per share

Price target increased to ₩199,000

Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes

Daewoong Pharmaceutical of South Korea Announces PRS-Inhibitor for Idiopathic Pulmonary Fibrosis Shows Promising Result in Early Stage Clinical Test

First quarter 2021 earnings released: ₩2,139 loss per share (vs ₩65.00 profit in 1Q 2020)

Price target increased to ₩147,143

Evolus, Inc. and Daewoong Pharmaceuticals Co., Ltd. Enter into Settlement Agreement

Full year 2020 earnings released: EPS ₩1,196 (vs ₩2,132 in FY 2019)

Daewoong pharmaceutical Co.,Ltd., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩121,000

Price target raised to ₩126,625

New 90-day high: ₩119,000

Third quarter 2020 earnings released: EPS ₩223

Price target lowered to ₩110,000

New 90-day low: ₩91,900

Daewoong Pharmaceutical Announces Korea's First-Ever SGLT2 Inhibitor for Diabetes Treatment

Price target lowered to ₩123,214

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken